Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director · CEO | March 16, 2024 | March 26, 2024 |
| EyePoint, Inc.EYPT · Entity 5702 | Director | August 18, 2026 | August 18, 2026 |
| VIVEVE MEDICAL, INC.VIVE · Entity 11899 | Director | November 26, 2019 | November 27, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date March 16, 2024 · Filed March 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,157,593 |
Reported balance
After 2024-03-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-03-16 · Exercise / conversion · Acquired 84,847 · Balance 1,157,593 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. |
| Common StockSEC Table I · non-derivative | Direct | 1,124,565 |
Reported balance
After 2024-03-21 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-03-21 · Sale · Disposed 33,028 · Balance 1,124,565 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 1,137,065 |
Reported balance
After 2024-03-16 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2024-03-16 · Exercise / conversion · Acquired 12,500 · Balance 1,137,065 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. |
| Common StockSEC Table I · non-derivative | Direct | 1,133,979 |
Reported balance
After 2024-03-21 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2024-03-21 · Sale · Disposed 3,086 · Balance 1,133,979 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 1,146,954 |
Reported balance
After 2024-03-16 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2024-03-16 · Exercise / conversion · Acquired 12,975 · Balance 1,146,954 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. |
| Common StockSEC Table I · non-derivative | Direct | 1,143,788 |
Reported balance
After 2024-03-21 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2024-03-21 · Sale · Disposed 3,166 · Balance 1,143,788 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 84,847 |
Reported balance
After 2024-03-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-16 · Exercise / conversion · Disposed 84,847 · Balance 84,847 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,500 |
Reported balance
After 2024-03-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-16 · Exercise / conversion · Disposed 12,500 · Balance 12,500 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-16 · Exercise / conversion · Disposed 12,975 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 ..
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F6: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
EyePoint, Inc.
Report date August 18, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,100 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Purchase · Acquired 10,600 · Balance 49,100 |
VIVEVE MEDICAL, INC.
Report date November 26, 2019 · Filed November 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2029-11-25 | Direct | 330,000 |
Reported balance
After 2019-11-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-26 · Grant · Acquired 330,000 · Balance 330,000 F1: The stock option shall vest and become exercisable in 48 equal monthly installments after November 26, 2019, subject to the Reporting Person's continuous service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest and become exercisable in 48 equal monthly installments after November 26, 2019, subject to the Reporting Person's continuous service to the Issuer through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2021 Filed Dec 22, 2021 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,243 | $9.24 | $11,485.32 |
DisclosureSEC source: 0000805928-21-000177 · wf-form4_164020733379564.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 923,029 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000177 · wf-form4_164020733379564.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2021. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 52,375 | $8.95 Strike: $8.95 | $468,756.25 |
DisclosureSEC source: 0000805928-21-000171 · wf-form4_163822016284363.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,125 Underlying: Common Stock · 52,375 shares Expires 2026-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. F2 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option will be fully vested on December 29, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 52,375 | $8.95 | $468,756.25 |
DisclosureSEC source: 0000805928-21-000171 · wf-form4_163822016284363.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 921,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 46,500 | $3.67 Strike: $3.67 | $170,655.00 |
DisclosureSEC source: 0000805928-21-000165 · wf-form4_162914459993109.xml · derivative · entry 4 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,500 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. F3 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 29, 2018 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2015 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 46,500 | $3.67 | $170,655.00 |
DisclosureSEC source: 0000805928-21-000165 · wf-form4_162914459993109.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 868,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,254 | $5.09 Strike: $5.09 | $42,012.86 |
DisclosureSEC source: 0000805928-21-000165 · wf-form4_162914459993109.xml · derivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,746 Underlying: Common Stock · 8,254 shares Expires 2022-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. F2 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 28, 2019 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 28, 2016 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 8,254 | $5.09 | $42,012.86 |
DisclosureSEC source: 0000805928-21-000165 · wf-form4_162914459993109.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 20:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 75,000 | $5.09 Strike: $5.09 | $381,750.00 |
DisclosureSEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · derivative · entry 6 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 75,000 shares Expires 2022-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. F6 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 29, 2019 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2016 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 20:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 75,000 | $5.09 | $381,750.00 |
DisclosureSEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:52 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 2,083 | $19.16 | $39,910.28 |
DisclosureSEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · nonDerivative · entry 5 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 814,018 F5 · shares: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with the November 19, 2018 and December 19, 2018 stock option exercises. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.075 to 19.40, inclusive. F5 · price: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with the November 19, 2018 and December 19, 2018 stock option exercises. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.075 to 19.40, inclusive. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:52 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 22,902 | $18.41 | $421,625.82 |
DisclosureSEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · nonDerivative · entry 4 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,101 F4 · shares: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with the November 19, 2018 and December 19, 2018 stock option exercises. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to 18.69, inclusive. F4 · price: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with the November 19, 2018 and December 19, 2018 stock option exercises. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to 18.69, inclusive. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:52 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 1,259 | $19.18 | $24,147.62 |
DisclosureSEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · nonDerivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 839,003 F3 · shares: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with a performance stock award that vested on February 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.08 to 19.40, inclusive. F3 · price: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with a performance stock award that vested on February 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.08 to 19.40, inclusive. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:52 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 14,756 | $18.40 | $271,510.40 |
DisclosureSEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840,262 F2 · shares: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with a performance stock award that vested on February 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to 18.69, inclusive. The reporting person undertakes to provide to Axogen, Inc., any security holder of Axogen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4. F2 · price: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with a performance stock award that vested on February 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to 18.69, inclusive. The reporting person undertakes to provide to Axogen, Inc., any security holder of Axogen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 20:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 8,812 | $19.20 | $169,190.40 |
DisclosureSEC source: 0000805928-21-000146 · wf-form4_162689849261026.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 780,018 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 22,077 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000146 · wf-form4_162689849261026.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,830 F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 100,000 | $5.09 Strike: $5.09 | $509,000.00 |
DisclosureSEC source: 0000805928-21-000074 · wf-form4_161894935065728.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 100,000 shares Expires 2022-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 29, 2019 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vested on December 29, 2016 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vested each 6 months thereafter. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 100,000 | $5.09 | $509,000.00 |
DisclosureSEC source: 0000805928-21-000074 · wf-form4_161894935065728.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,500 | $3.67 Strike: $3.67 | $56,885.00 |
DisclosureSEC source: 0000805928-21-000069 · wf-form4_161704904152217.xml · derivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,500 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 19,000 | $3.67 Strike: $3.67 | $69,730.00 |
DisclosureSEC source: 0000805928-21-000069 · wf-form4_161704904152217.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 34,500 | $3.67 | $126,615.00 |
DisclosureSEC source: 0000805928-21-000069 · wf-form4_161704904152217.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:54 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000061 · wf-form4_161610446437517.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:54 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 76,600 | $0.00 Strike: $20.91 | $0.00 |
DisclosureSEC source: 0000805928-21-000061 · wf-form4_161610446437517.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,600 Underlying: Common Stock · 76,600 shares Expires 2031-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2025 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 3,504 | $18.71 | $65,559.84 |
DisclosureSEC source: 0000805928-21-000021 · wf-form4_161368648138970.xml · nonDerivative · entry 4 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 631,412 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 4,182 | $18.71 | $78,245.22 |
DisclosureSEC source: 0000805928-21-000021 · wf-form4_161368648138970.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,938 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 13,978 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000021 · wf-form4_161368648138970.xml · nonDerivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,916 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 16,021 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000021 · wf-form4_161368648138970.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,120 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:08 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 65,000 | $20.00 | $1,300,000.00 |
DisclosureSEC source: 0001179110-21-000537 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,099 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2020. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:53 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 3,500 | $17.81 | $62,335.00 |
DisclosureSEC source: 0001179110-20-012286 · edgar.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674,099 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 16:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 8,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012286 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 677,599 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. F3 · balance_after: Includes 2705 shares acquired under the Axogen, Inc. employee stock purchase plan on June 30, 2020. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 14:26 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 19,375 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001179110-20-012230 · edgar.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,375 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 14:26 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 19,375 | $4.81 | $93,193.75 |
DisclosureSEC source: 0001179110-20-012230 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 22:32 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 1,275 | $16.42 | $20,935.50 |
DisclosureSEC source: 0001179110-20-012189 · edgar.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,719 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 22:32 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 3,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012189 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,994 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2020. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 14:56 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 14,000 | $14.53 | $203,420.00 |
DisclosureSEC source: 0001179110-20-010948 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,869 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2020. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 12:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,625 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001179110-20-004980 · edgar.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,625 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 12:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 11,625 | $4.81 | $55,916.25 |
DisclosureSEC source: 0001179110-20-004980 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the cash exercise of a stock option for a total of 11,625 shares. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 51,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003910 · edgar.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,900 Underlying: Common Stock · 51,900 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 80,200 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001179110-20-003910 · edgar.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,200 Underlying: Common Stock · 80,200 shares Expires 2030-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2024 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:17 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 16,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001957 · edgar.xml · nonDerivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,244 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 5,429 | $14.68 | $79,697.72 |
DisclosureSEC source: 0001179110-20-001957 · edgar.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 631,229 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:17 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 13,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001957 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,658 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| January 01, 2020 Filed Jan 18, 2020 01:41 UTC | Axogen, Inc. AXGN · Entity 4297 | Disposition to issuerCommon Stock | 10,112 | $17.34 | $175,342.08 |
DisclosureSEC source: 0001179110-20-000664 · edgar.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,680 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on January 1, 2020. Read SEC document |
| January 01, 2020 Filed Jan 18, 2020 01:41 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-000664 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,792 F1 · shares: This reflects the number of restricted stock units that became vested as of January 1, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of January 1, 2020. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:28 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-013087 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,530 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2019. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2019. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 19:30 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 330,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001437749-19-023671 · rdgdoc.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2029-11-25 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in 48 equal monthly installments after November 26, 2019, subject to the Reporting Person's continuous service to the Issuer through each such date. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 12:59 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 75,000 | $13.50 | $1,012,425.00 |
DisclosureSEC source: 0001179110-19-009360 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,280 Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 17:49 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 37,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-013405 · rdgdoc.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,347 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 37,829 shares of common stock on July 1, 2019 (the "Grant Date") in lieu of quarterly cash fees pursuant to the Issuer's Independent Director Compensation Policy. The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 18,056 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001179110-19-006887 · edgar.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,056 shares Expires 2019-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 18,056 | $0.27 | $4,875.12 |
DisclosureSEC source: 0001179110-19-006887 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.